Healthcare provider profile · identity verified

Madhupreet Hans, DO

Family Practice · ROSEVILLE, CA · NPI 1659864080

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	217	77
Losartan Potassium	Losartan Potassium	170	49
Levothyroxine Sodium	Levothyroxine Sodium	144	55
Lisinopril	Lisinopril	127	41
Omeprazole	Omeprazole	114	36
Hydrochlorothiazide	Hydrochlorothiazide	109	36
Amlodipine Besylate	Amlodipine Besylate	102	37
Gabapentin	Gabapentin	97	28
Simvastatin	Simvastatin	93	28
Metoprolol Succinate	Metoprolol Succinate	68	23
Metformin Hcl	Metformin Hcl	65	24
Trazodone Hcl	Trazodone Hcl	64	17
Rosuvastatin Calcium	Rosuvastatin Calcium	57	19
Eliquis	Apixaban	49	16
Furosemide	Furosemide	49	17
Famotidine	Famotidine	46	20
Fluticasone Propionate	Fluticasone Propionate	46	22
Potassium Chloride	Potassium Chloride	46	14
Sertraline Hcl	Sertraline Hcl	44	12
Quetiapine Fumarate	Quetiapine Fumarate	43	13
Escitalopram Oxalate	Escitalopram Oxalate	41	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	41	17
Citalopram Hbr	Citalopram Hydrobromide	40	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	39	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	37	12
Donepezil Hcl	Donepezil Hcl	36	suppressed
Alendronate Sodium	Alendronate Sodium	35	12
Allopurinol	Allopurinol	35	suppressed
Carvedilol	Carvedilol	32	suppressed
Estradiol	Estradiol	30	suppressed
Ozempic	Semaglutide	30	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	11
Meloxicam	Meloxicam	29	suppressed
Montelukast Sodium	Montelukast Sodium	27	suppressed
Spironolactone	Spironolactone	27	suppressed
Finasteride	Finasteride	26	suppressed
Myrbetriq	Mirabegron	26	suppressed
Lovastatin	Lovastatin	24	suppressed
Glipizide Er	Glipizide	22	suppressed
Metformin Hcl Er	Metformin Hcl	22	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	22	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	21	11
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Memantine Hcl	Memantine Hcl	19	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	18	suppressed
Lorazepam	Lorazepam	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Tramadol Hcl	Tramadol Hcl	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Lamotrigine	Lamotrigine	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Atenolol	Atenolol	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Colchicine	Colchicine	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Prevalite	Cholestyramine	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error